期刊文献+

群体药动学在免疫抑制剂合理用药中的应用 被引量:4

Application of population pharmacokinetics in the rational usage of immunosuppressive drugs
下载PDF
导出
摘要 群体药动学(PPK)应用统计学原理,综合评价影响药动学个体间及个体内差异的各种因素,进一步利用Bayesian反馈,能够较为准确地预测患者个体药动学参数。PPK在免疫抑制剂环孢素、他克莫司、霉酚酸及西罗莫司的合理用药均有广泛应用。 Population pharmacokinetics ( PPK ), which is based on the principle of statistics, can be used to estimate various inter- and intra-individual factors which affect pharmacokinetics. By using Bayesian estimator, PPK can predict individual pharmacokinetic parameters accurately. PPK is widely used in the im-munosuppressive therapy with cyclosporine, tacrolimus, mycophenolle acid and sirolimus.
作者 陈冰 蔡卫民
出处 《中国药理学通报》 CAS CSCD 北大核心 2010年第2期159-163,共5页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助项目(No30500626)
关键词 群体药动学(PPK) 免疫抑制剂 环孢素A 他克莫 霉酚酸 西罗莫司 population pharmaeokinetics ( PPK ) immunosuppressive drugs cyclosporine A tacrolimus myphonolic acid sirolimus
  • 相关文献

参考文献25

  • 1Meierkriesche H U, Schold J D, Kaplan B. Long-term renal allograft survival:have we made significant progress or is it time to rethink our analytic and therapeutic strategies [ J ] ? Am J Transplant, 2004,4(8) :1289 -95.
  • 2Brendel K, Dartois C,Comets E,et al. Are population pharmacokinetie and/or phannaeodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 [ J ]. Clin Pharmacokinet,2007,46 ( 3 ) :221 - 34.
  • 3Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetie modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator [ J]. Ther Drug Monit ,2004,26 ( 1 ) :23 - 30.
  • 4Wu K H, Cui Y M, Guo J F, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients [J]. Drug Metab Dispos ,2005,33 (9) : 1268 - 75.
  • 5Rosenbaum S E, Baheti G, Trull A K, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients [ J ]. Ther Drug Monit,2005,27 ( 2 ) : 116 - 22.
  • 6Schadeli F, Marti H P, Frey F J, Uehlinger D E. Population pharmacokinetie model to predict steady-state exposure to once-daily eyclosporin mieroemulsion in renal transplant recipients [ J]. Clin Pharmacokinet ,2002,41 ( 1 ) :59 - 69.
  • 7Fanta S, Jonsson S, Backman J T, et al. Developmental phannacokinetics of ciclosporin-a population pharmacokinetic study in paediatile renal transplant candidates[J]. Br J Clin Pharmaeo1,2007 ,64 (6) :772 -84.
  • 8Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients[J]. Ther Drug Monit,2007,29( 1 ) :96 - 102.
  • 9Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart,lung and kidney transplant patients[ J]. Clin Pharmacokinet ,2006,45 (9) :905 -22.
  • 10Hesselink D A, van Gelder T, van Schaik R H, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1 ,CYP3A4,and CYP3A5 genes[J]. Clin Pharmacol Ther,2004,76(6) :545 -56.

二级参考文献21

  • 1成碟,徐为人,刘昌孝.细胞色素P450(CYP450)遗传多态性研究进展[J].中国药理学通报,2006,22(12):1409-1414. 被引量:44
  • 2薛永志,刘和莉,李月玲,武海军,张东.苯巴比妥钠对免疫性肝损伤鼠肝脏iNOS和CYP450的作用[J].中国药理学通报,2007,23(1):138-139. 被引量:4
  • 3Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve [J]. Transplantation, 1999 ,68( 1 ) :55 -62.
  • 4Evans W E, McLeod H L. Pharmacogenomics-Drug disposition, drug targets and side effects [ J ]. N Engl J Med, 2003,348 ( 6 ) : 538 - 49.
  • 5Weinshilboum R. Inheritance and drug response [ J ]. N Engl J Med, 2003,348(6) :529 -37.
  • 6Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004,23( 1 ) :100 -8.
  • 7Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos [ J ]. J Pharmacol Exp Ther, 2001,299 (3) :825 -31.
  • 8Chou F C, Tzeng S J, Huang J D. Genetic polymorphism of cytochrome P450 3A5 in Chinese [ J]. Drug Metab Dispos, 2001,29 (9) :1205 -9.
  • 9Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001,27(4) :383 -91.
  • 10Hu Y F, Tu J H, Tan Z R, et al. Association of CYP3A4* 18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects [ J ]. Xenobiotica, 2007,37 ( 3 ) :315 - 27.

共引文献36

同被引文献38

引证文献4

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部